...取最新 硼替佐米诱导骨髓瘤细胞未折迭蛋白反应及凋亡 董红娟 【摘要】: 背景和目的:蛋白酶体抑制剂(proteasome inhibitor, PI)作为一类新型抗肿瘤药物,自2003年被美国FDA批准用于治疗复发难治性多发性骨髓瘤(multiple...
基于294个网页-相关网页
...抑制剂诱导的PC12细胞帕金森病模型中血红素加氧酶-1的差异表达 加入收藏夹 目的 探讨蛋白酶体抑制剂(Proteasome inhibitor,PSI)诱导的PC12细胞帕金森病(Parkinson disease,PD)模型中血红素加氧酶-1(Hem...
基于2个网页-相关网页
Proteasome inhibitor PS-341 蛋白酶体抑制剂PS
proteasome inhibitor ps- 蛋白酶体抑制剂ps
proteasome inhibitor MG132 蛋白酶体抑制剂MG
ubiquitin-proteasome inhibitor 抑制剂
Proteasome inhibitor Bortezomib 蛋白酶体抑制剂Bortezomib
proteasome inhibitor MG-132 蛋白酶体抑制剂MG
以上来源于: WordNet
Bortezonib (velcade) is the first proteasome inhibitor that has entered clinical trial.
波替单抗(万珂)是第一个进入临床试验的蛋白酶体抑制剂。
The proteasome inhibitor MG-132 can reduce the lung injury induced by hyperoxia and inhibit P38MAPK signaling pathway.
蛋白酶体抑制剂MG - 132可以减轻高氧引起的肺损伤,可能对p 38 MAPK信号通路有抑制作用。
AIM: to investigate effects of ubiquitin-proteasome inhibitor on proliferation and apoptosis of gastric carcinoma cells.
目的:研究泛素蛋白酶体抑制剂对胃癌细胞增殖和凋亡的影响。
应用推荐